Yuhan Corporation's Gaucher Disease Drug Candidate 'YH35995' Designated as Orphan Drug by European EMA

Yuhan Corporation announced on the 23rd that its new drug candidate 'YH35995', currently being developed as a treatment for ...
STAT

As its immunology work draws attention, Sanofi also pushes forward in rare disease

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Sanofi’s Cerezyme has long been used ...

Yuhan's Gaucher disease drug candidate wins EMA orphan drug designation

Yuhan announced Tuesday that its drug candidate YH35995, under development as a treatment for Gaucher disease, has received ...
Medical Xpress

Improving the recipe for gene therapy: New treatment for Gaucher disease shows promise

Gregory and Deborah Macres from California lost their son, Gregory, in 1997, when he was just 4 years old. Little Gregory had a severe form of a rare genetic disorder called Gaucher disease and died ...
FiercePharma

Experimental gene therapies on the cusp to ‘disrupt’ Gaucher disease drug market: GlobalData

The Gaucher disease market is currently dominated by drugs that replace enzymes, but a gene therapy approach could prove curative and much more attractive to HCPs, say GlobalData. (Oleg Elkov/Getty) ...
Monthly Prescribing Reference

Venglustat Improves Neurological Symptoms in Type 3 Gaucher Disease

Venglustat significantly improved neurological symptoms in patients with type 3 Gaucher disease compared with enzyme replacement therapy. Venglustat, an investigational glucosylceramide (GL-1) ...